Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt

European Journal of Gastroenterology and Hepatology

Volumn 23, Issue 12, 2011, Pages 1218-1225

  Trebicka, Jonel ^a,c   Krag, Aleksander ^c   Gansweid, Stefan ^a   Appenrodt, Beate ^a   Schiedermaier, Peter ^a,b   Sauerbruch, Tilman ^a   Spengler, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b Zweibrücken Hospital   (Germany)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cirrhosis; endotoxin; portal hypertension; transjugular intrahepatic portosystemic shunt; tumor necrosis factor

Indexed keywords

CHOLINESTERASE; ENDOTOXIN; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 55; SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 75; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTERIAL PRESSURE; ARTICLE; ASCITES; BIOCHEMISTRY; BLEEDING; BLOOD SAMPLING; CLINICAL ARTICLE; END STAGE LIVER DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMODYNAMIC PARAMETERS; HEPATIC VEIN; HUMAN; MALE; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VEIN BLOOD FLOW;

ADULT; AGED; AGED, 80 AND OVER; BLOOD FLOW VELOCITY; BLOOD PRESSURE; ENDOTOXINS; FEMALE; FOLLOW-UP STUDIES; HEPATIC VEINS; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PORTAL VEIN; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; ULTRASONOGRAPHY, DOPPLER;

EID: 80955148930     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32834a75dc     Document Type: Article

References (48)

1. Caly WR, E Strauss. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol 1993; 18:353-358. (Pubitemid 23279724)
2. Garcia-Tsao G R Wiest. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004; 18:353-372. (Pubitemid 38444136)
3. Nolan JP, Ali MV. Letter: Kupffer cells and cirrhosis. Lancet 1975; 1:449.
4. Thulstrup AM, Sorensen HT, Schønheyder HC, Møller JK, Tage-Jensen U. Population-based study of the risk and short-term prognosis for bacteremia in patients with liver cirrhosis. Clin Infect Dis 2000; 31:1357-1361.
5. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41:422-433. (Pubitemid 40289486)
6. Diez-Ruiz A, Tilz GP, Zangerle R, Baier-Bitterlich G, Wachter H, Fuchs D. Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995; 54:1-8.
7. Nophar Y, Kemper O, Brakebusch C, Englemann H, Zwang R, Aderka D, et al. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 9:3269-3278.
8. Aukrust P, Liabakk NB, Müller F, Lien E, Espevik T, Frøland SS. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994; 169:420-424. (Pubitemid 24045606)
9. Zangerle R, Gallati H, Sarcletti M, Wachter H, Fuchs D. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection. Immunol Lett 1994; 41:229-234. (Pubitemid 24279494)
10. Deviere J, Content J, Denys C, Vandenbussche P, Schandene L, Wybran J, Dupont E. Excessive in vitro bacterial lipopolysaccharide-induced production of monokines in cirrhosis. Hepatology 1990; 11:628-634. (Pubitemid 20151741)
11. Genesca J, Marti R, Campos F, Peribáñez V, Gónzalez A, Castellas L, et al. Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites. Gut 2003; 52:1054-1059. (Pubitemid 36765301)
12. Nolan JP. The role of intestinal endotoxin in liver injury: a long and evolving history. Hepatology 2011; 52:1829-1835.
13. Bernard B, Cadranel JF, Escolano S, Jarlier V, Opolon P. Prognostic significance of bacterial infection in bleeding cirrhotic patients: a prospective study. Gastroenterology 1995; 108:1828-1834.
14. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Francitorra A, et al. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology 1994; 20:1495-1501. (Pubitemid 24359062)
15. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998; 27:1207-1212. (Pubitemid 28227845)
16. Wiest R, Cadelina G, Milstien S, McCuskey RS, Garcia-Tsao G, Groszmann RJ. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology 2003; 38:1508-1515. (Pubitemid 37466977)
17. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104:1223-1233. (Pubitemid 29536293)
18. Thabut D, Tazi KA, Bonnefont-Rousselot D, Aller M, Farges O, Guimont MC, et al. High-density lipoprotein administration attenuates liver proinflammatory response, restores liver endothelial nitric oxide synthase activity, and lowers portal pressure in cirrhotic rats. Hepatology 2007; 46:1893-1906.
19. Albillos A, Hera Ad Ade L, Reyes E, Monserrat J, Muñoz L, Nieto M, et al. Tumour necrosis factor-alpha expression by activated monocytes and altered T-cell homeostasis in ascitic alcoholic cirrhosis: amelioration with norfloxacin. J Hepatol 2004; 40:624-631. (Pubitemid 38367784)
20. Gines P, Rimola A, Planas R, Vargas V, Marco F, Almela M, et al. Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. Hepatology 1990; 12 (4 Pt 1): 716-724. (Pubitemid 20349256)
21. Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998; 29:430-436. (Pubitemid 28396660)
22. Rimola A, Bory F, Teres J, Perez-Ayuso RM, Arroyo V, Rodes J. Oral, nonabsorbable antibiotics prevent infection in cirrhotics with gastrointestinal hemorrhage. Hepatology 1985; 5:463-467. (Pubitemid 15065955)
23. Soriano G, Guarner C, Tomás A, Villanueva C, Torras X, Gonzá lez D, et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 1992; 103:1267-1272.
24. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis A randomized trial. Ann Intern Med 2003; 139:186-193.
25. Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K, Manolakopoulos S, et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol-related decompensated cirrhosis. Aliment Pharmacol Ther 2009; 29:992-999.
26. Deschenes M, Villeneuve JP. Risk factors for the development of bacterial infections in hospitalized patients with cirrhosis. Am J Gastroenterol 1999; 94:2193-2197. (Pubitemid 29374553)
27. Fernandez J, Navasa M, Gómez J, Colmenero J, Vila J, Arroyo V, Rodés J. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology 2002; 35:140-148. (Pubitemid 34032554)
28. Yoshida H, Hamada T, Inuzuka S, Ueno T, Sata M, Tanikawa K. Bacterial infection in cirrhosis, with and without hepatocellular carcinoma. Am J Gastroenterol 1993; 88:2067-2071. (Pubitemid 23352173)
29. Wiest R, Rath HC. Gastrointestinal disorders of the critically ill. Bacterial translocation in the gut. Best Pract Res Clin Gastroenterol 2003; 17: 397-425.
30. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995; 22:165-172.
31. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988; 8:232-236.
32. Brensing KA, Horsch M, Textor J, Schiedermaier P, Raab P, Schepke M, et al. Hemodynamic effects of propranolol and nitrates in cirrhotics with transjugular intrahepatic portosystemic stent-shunt. Scand J Gastroenterol 2002; 37:1070-1076.
33. Brensing KA, Textor J, Perz J, Schiedermaier P, Raab P, Strunk H, et al. Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000; 47:288-295. (Pubitemid 30489776)
34. Schiedermaier P, Koch L, Mojón A, Hermida R, Layer G, Sauerbruch T. Circadian rhythm of fasting and postprandial portal blood flow in cirrhosis. Scand J Gastroenterol 2006; 41:826-832. (Pubitemid 43941242)
35. Jalan R, Olde Damink SW, Ter Steege JC, Redhead DN, Lee A, Hayes PC, Deutz NE. Acute endotoxemia following transjugular intrahepatic stent-shunt insertion is associated with systemic and cerebral vasodilatation with increased whole body nitric oxide production in critically ill cirrhotic patients. J Hepatol 2011; 54:265-271.
36. Garcia-Tsao G. Bacterial translocation: cause or consequence of decompensation in cirrhosis? J Hepatol 2001; 34:150-155.
37. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009; 50:638-644.
38. Tazi KA, Moreau R, Hervé P, Dauvergne A, Cazals-Hatem D, Bert F, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signalling. Gastroenterology 2005; 129:303-314. (Pubitemid 41002062)
39. Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: a role for nitric oxide. Lancet 1991; 337:776-778.
40. Ekataksin W, Kaneda K. Liver microvascular architecture: an insight into the pathophysiology of portal hypertension. Semin Liver Dis 1999; 19:359-382. (Pubitemid 30032639)
41. Hennenberg M, Trebicka J, Sauerbruch T, Heller J. Mechanisms of extrahepatic vasodilation in portal hypertension. Gut 2008; 57:1300-1314.
42. Chu CJ, Lee FY, Wang SS, Lu RH, Tsai YT, Lin HC, et al. Hyperdynamic circulation of cirrhotic rats with ascites: role of endotoxin, tumour necrosis factor-alpha and nitric oxide. Clin Sci (Lond) 1997; 93:219-225.
43. Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: relationship to endotoxemia. Hepatology 1993; 18:1139-1143. (Pubitemid 23320445)
44. Braude AI, Carey FJ, Zalesky M. Studies with radioactive endotoxin. II. Correlation of physiologic effects with distribution of radioactivity in rabbits injected with radioactive sodium chromate. J Clin Invest 1955; 34:858-866.
45. Freudenberg MA, Freudenberg N, Galanos C. Time course of cellular distribution of endotoxin in liver, lungs and kidneys of rats. Br J Exp Pathol 1982; 63:56-65. (Pubitemid 12191887)
46. Mathison JC, Ulevitch RJ. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 1979; 123:2133-2143. (Pubitemid 10194464)
47. Katz S, Grosfeld JL, Gross K, Plager DA, Ross D, Rosenthal RS, et al. Impaired bacterial clearance and trapping in obstructive jaundice. Ann Surg 1984; 199:14-20. (Pubitemid 14218868)
48. Martin TR, Mathison JC, Tobias PS, Letúrcq DJ, Moriarty AM, Maunder RJ, Ulevitch RJ. Lipopolysaccharide binding protein enhances the responsiveness of alveolar macrophages to bacterial lipopolysaccharide. Implications for cytokine production in normal and injured lungs. J Clin Invest 1992; 90:2209-2219. (Pubitemid 23010034)